[go: up one dir, main page]

MX2012012095A - Analogos de tiazolidinadiona. - Google Patents

Analogos de tiazolidinadiona.

Info

Publication number
MX2012012095A
MX2012012095A MX2012012095A MX2012012095A MX2012012095A MX 2012012095 A MX2012012095 A MX 2012012095A MX 2012012095 A MX2012012095 A MX 2012012095A MX 2012012095 A MX2012012095 A MX 2012012095A MX 2012012095 A MX2012012095 A MX 2012012095A
Authority
MX
Mexico
Prior art keywords
thiazolidinedione analogues
thiazolidinedione
analogues
nonalcoholic
afflictions
Prior art date
Application number
MX2012012095A
Other languages
English (en)
Inventor
Robert C Gadwood
Gerard R Colca
Timothy Parker
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of MX2012012095A publication Critical patent/MX2012012095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a análogos de tiazolidinadiona que son útiles para tratar aflicciones del hígado tal como enfermedad no alcohólica de hígado graso (NAFLD) o esteatohepatitis no alcohólica (NASH).
MX2012012095A 2010-04-21 2011-04-20 Analogos de tiazolidinadiona. MX2012012095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32640010P 2010-04-21 2010-04-21
PCT/US2011/033145 WO2011133611A1 (en) 2010-04-21 2011-04-20 Thiazolidinedione analogues

Publications (1)

Publication Number Publication Date
MX2012012095A true MX2012012095A (es) 2012-12-17

Family

ID=44227561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012095A MX2012012095A (es) 2010-04-21 2011-04-20 Analogos de tiazolidinadiona.

Country Status (10)

Country Link
US (1) US20130281414A1 (es)
EP (1) EP2560615A1 (es)
JP (1) JP2013525362A (es)
KR (1) KR20130064742A (es)
CN (1) CN102946860A (es)
AU (1) AU2011242844A1 (es)
CA (1) CA2796961A1 (es)
MX (1) MX2012012095A (es)
RU (1) RU2012149458A (es)
WO (1) WO2011133611A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2783468C (en) 2009-12-15 2018-10-09 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
EP3787618A4 (en) 2018-05-04 2022-05-04 Cirius Therapeutics, Inc. THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
WO2020033447A1 (en) * 2018-08-07 2020-02-13 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Compositions acting as (pro) renin receptor antagonists for the treatment of non-alcoholic fatty liver disease
WO2020146810A1 (en) * 2019-01-10 2020-07-16 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
EP4054568A4 (en) * 2019-11-08 2023-12-13 Cirius Therapeutics, Inc. THIAZOLIDINDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
CN115916762A (zh) * 2020-08-18 2023-04-04 梅特雷亚生物科学股份有限公司 调节17β-羟基类固醇脱氢酶13型的化合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
NO302471B1 (no) * 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
NZ583889A (en) * 2007-09-14 2012-01-12 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension
US8722710B2 (en) * 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone

Also Published As

Publication number Publication date
EP2560615A1 (en) 2013-02-27
KR20130064742A (ko) 2013-06-18
AU2011242844A1 (en) 2012-11-01
US20130281414A1 (en) 2013-10-24
CN102946860A (zh) 2013-02-27
JP2013525362A (ja) 2013-06-20
RU2012149458A (ru) 2014-05-27
WO2011133611A1 (en) 2011-10-27
CA2796961A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
MX2012012095A (es) Analogos de tiazolidinadiona.
GEP201706663B (en) Novel composition for nonalcoholic fatty liver disease (nafld
IL228988A (en) Antibody preparations for the treatment of vaccine-related diseases
MY152282A (en) Compositions and methods for use antibodies against sclerostin
AP2960A (en) Substituted pyrimidines for the treatment of diseases such as cancer
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
IN2014KN00848A (es)
GB0917002D0 (en) Improved shigella blebs
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
PL2445510T3 (pl) Kompozycja do leczenia zwyrodnieniowych chorób stawów
IL251083A0 (en) Compounds and preparations for the treatment of cancer
PH12013500529A1 (en) Methods and compositions for treating lung cancer
MX2019005082A (es) Composiciones que comprenden 15-ohepa y metodos para usar las mismas.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
PT2605764E (pt) Composições para o tratamento de cancro
WO2012024282A3 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
IN2014DN07326A (es)
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
GB0917745D0 (en) Compositions for the prevention or treatment of migraine
PT2566506T (pt) Composição de vacina para a prevenção ou tratamento de leishmanioses
TN2010000463A1 (en) Compositions and methods for preparing and using same
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
IL223055A0 (en) Compositions for the treatment of gynaecological disorders
IN2012DN02721A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal